Janssen-Cilag Ltd.

RYBREVANT and LAZCLUZE Combination Shows Significant Survival Improvement in EGFR-Mutated NSCLC

5 months ago

• Johnson & Johnson's RYBREVANT plus LAZCLUZE demonstrates statistically significant and clinically meaningful improvement in overall survival (OS) versus osimertinib in EGFR-mutated NSCLC. • The MARIPOSA Phase 3 study showed the chemotherapy-free combination is expected to improve median OS by over one year compared to the current standard of care. • RYBREVANT plus LAZCLUZE is approved in the U.S. and Europe as a first-line therapy for NSCLC patients with EGFR exon 19 deletions or L858R substitution mutations. • The safety profile of the combination was consistent with individual treatments, with venous thromboembolic events managed through prophylactic anticoagulants.

RSV Emerges as Hidden Threat to Elderly Population, Causing 8,000 Annual Deaths in UK

2 years ago

• Respiratory Syncytial Virus (RSV) significantly impacts older adults, with 79% of adult RSV hospitalizations occurring in those aged 65+ years and causing approximately 8,000 deaths annually in the UK. • The virus is frequently misdiagnosed due to symptoms similar to COVID-19 and flu, leading to severe underestimation of cases and delayed treatment in elderly populations. • RSV creates substantial societal burden through economic impact, care home transmission risks, and disruption of family care structures, highlighting urgent need for increased awareness and testing.